The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Subjects will receive somapacitan-beco (Sogroya®) administered as a subcutaneous injection once weekly for 12 weeks. All participants will receive a fixed dose of 1.5 mg weekly, regardless of sex.
Mayo Clinic
Phoenix, Arizona, United States
RECRUITINGMayo Clinic in Arizona
Scottsdale, Arizona, United States
RECRUITINGGastroparesis Cardinal Symptom Index (GCSI)
The Gastroparesis Cardinal Symptom Index (GCSI) is a questionnaire that assesses the severity of gastroparesis symptoms of: nausea, early satiety, postprandial fullness, and upper abdominal pain. Scores range from 0-none to 4-very severe.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks
Complete Spontaneous Bowel Movements (CSBMs)
Number of bowel movements, without the aid of laxatives, after which the patient has the sensation of complete defecation.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks
Gastrointestinal Patient Reported Outcomes Measurement Information System (GI- PROMIS)
The Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) scale assess 8 domains: gastroesophageal reflux, disrupted swallowing, diarrhea, bowel incontinence/soilage, nausea and vomiting, constipation, belly pain, and gas/bloat/flatulence. Scores are scaled so that an average healthy person would score 50 points. A higher score indicates worse gastrointestinal symptoms.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.